AQP4 and neuromyelitis optica: As about 70%–80% of NMO cases are associated with aquaporin‐4 antibodies, AQP4‐Ab testing is an essential tool for NMO diagnosis and consideration of treatment options, especially long‐term immunosuppression (Sellner et al., 2010).